Jason M Shohet
Overview
Explore the profile of Jason M Shohet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
1260
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rozen E, Frantz W, Wigglesworth K, Vessella T, Zhou H, Shohet J
Mol Cancer Ther
. 2024 Apr;
23(8):1124-1138.
PMID: 38670553
Oncogene-driven expression and activation of receptor tyrosine kinases promotes tumorigenesis and contributes to drug resistance. Increased expression of the kinases discoidin domain receptor 2 (DDR2), RET Proto-Oncogene (RET), Platelet Derived...
2.
Rozen E, Wigglesworth K, Shohet J
Biomedicines
. 2024 Jan;
12(1).
PMID: 38255303
High-risk neuroblastoma is a very aggressive pediatric cancer, accounting for ~15% of childhood cancer mortality. Therefore, novel therapeutic strategies for the treatment of neuroblastoma are urgently sought. Here, we focused...
3.
Huang L, Zhang X, Rozen E, Sun X, Sallis B, Verdejo-Torres O, et al.
Nat Commun
. 2022 Jul;
13(1):3955.
PMID: 35803962
Protein arginine methyltransferase 5 (PRMT5) is the primary methyltransferase generating symmetric-dimethyl-arginine marks on histone and non-histone proteins. PRMT5 dysregulation is implicated in multiple oncogenic processes. Here, we report that PRMT5-mediated...
4.
Whittle S, Smith V, Silverstein A, Parmeter M, Minard C, Bernhardt M, et al.
Pediatr Blood Cancer
. 2020 Jul;
67(10):e28417.
PMID: 32729196
Background/objectives: Standard supportive care during induction therapy for high-risk neuroblastoma (HR-NBL) includes primary prophylactic granulocyte colony-stimulating factor (G-CSF) aimed at limiting duration of neutropenia, reducing infection risk, and minimizing treatment...
5.
Agarwal S, Milazzo G, Rajapakshe K, Bernardi R, Chen Z, Eveline B, et al.
Oncotarget
. 2018 Jul;
9(52):30024.
PMID: 30042831
[This corrects the article DOI: 10.18632/oncotarget.24859.].
6.
Agarwal S, Milazzo G, Rajapakshe K, Bernardi R, Chen Z, Barbieri E, et al.
Oncotarget
. 2018 May;
9(29):20323-20338.
PMID: 29755654
The MYC oncogenes and p53 have opposing yet interrelated roles in normal development and tumorigenesis. How MYCN expression alters the biology and clinical responsiveness of pediatric neuroblastoma remains poorly defined....
7.
Tomolonis J, Agarwal S, Shohet J
Cell Tissue Res
. 2017 Dec;
372(2):245-262.
PMID: 29222693
Neuroblastoma (NB) is an aggressive pediatric cancer that originates from neural crest tissues of the sympathetic nervous system. NB is highly heterogeneous both from a clinical and a molecular perspective....
8.
Sun W, Rojas Y, Wang H, Yu Y, Wang Y, Chen Z, et al.
Oncotarget
. 2017 Dec;
8(55):94780-94792.
PMID: 29212266
Treatment failure in high risk neuroblastoma (NB) is largely due to the development of chemotherapy resistance. We analyzed the gene expression changes associated with exposure to chemotherapy in six high...
9.
Moreno-Smith M, Lakoma A, Chen Z, Tao L, Scorsone K, Schild L, et al.
Clin Cancer Res
. 2017 Aug;
23(21):6629-6639.
PMID: 28821555
mTORC1 inhibitors are promising agents for neuroblastoma therapy; however, they have shown limited clinical activity as monotherapy, thus rational drug combinations need to be explored to improve efficacy. Importantly, neuroblastoma...
10.
Hsu D, Shohet J, Kim E
Bio Protoc
. 2016 Aug;
4(8).
PMID: 27540563
Tumors are comprised of heterogeneous subpopulations that may exhibit differing capacity for differentiation, self-renewal, and tumorigenicity. lineage-tracing studies are a powerful tool for defining the role of tumor subpopulations in...